Current Hematologic Malignancy Reports

, Volume 13, Issue 3, pp 227–235 | Cite as

How We Manage Patients with Plasmacytomas

  • Despina Fotiou
  • Meletios A. Dimopoulos
  • Efstathios Kastritis
Multiple Myeloma (P Kapoor, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Multiple Myeloma


Purpose of Review

To discuss the diagnostic approach, treatment options, and future considerations in the management of plasmacytomas, either solitary or in the context of overt multiple myeloma (MM).

Recent Findings

Advanced imaging techniques such as whole-body magnetic resonance imaging and positron emission tomography/computerized tomography are essential for the diagnostic workup of solitary plasmacytomas (SP) to rule out the presence of other disease foci. The role of flow cytometry and clonal plasma cell detection is currently under study together with other prognostic factors for the identification of patients with SP at high risk of progression to overt MM. Solitary plasmacytomas are treated effectively with local radiotherapy whereas systemic therapy is required at relapse. Clonal plasma cells that accumulate at extramedullary sites have distinct biological characteristics. Patients with MM and soft tissue involvement have poor outcomes and should be treated as ultra-high risk.


A revised definition of SP that distinguishes between true solitary clonal PC accumulations and SP with minimal bone marrow involvement should be considered to guide an appropriate therapeutic and follow-up approach. Future studies should be conducted to determine optimum treatment approaches for patients with MM and paraskeletal or extramedullary disease.


Plasma cells Tumor Solitary lesion Bone disease Extramedullary  


Compliance with Ethical Standards

Conflict of Interest

Dr. Dimopoulos reports personal fees from Amgen, personal fees from Celgene, personal fees from Janssen, and personal fees from Takeda, during the conduct of the study. Dr. KASTRITIS reports personal fees from Amgen, personal fees from Genesis Pharma, personal fees from Janssen, personal fees from Takeda, and personal fees from Prothena, during the conduct of the study. Dr. Fotiou has nothing to disclose.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


  1. 1.
    Rajkumar SV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48.CrossRefPubMedGoogle Scholar
  2. 2.
    Moulopoulos LA, et al. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol. 1993;11(7):1311–5.CrossRefPubMedGoogle Scholar
  3. 3.
    Dimopoulos MA, et al. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood. 2000;96(6):2037–44.PubMedGoogle Scholar
  4. 4.
    Kilciksiz S, et al. A review for solitary plasmacytoma of bone and extramedullary plasmacytoma. Sci World J. 2012;2012:895765.CrossRefGoogle Scholar
  5. 5.
    Galieni P, et al. Clinical outcome of extramedullary plasmacytoma. Haematologica. 2000;85(1):47–51.PubMedGoogle Scholar
  6. 6.
    Knowling MA, Harwood AR, Bergsagel DE. Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone. J Clin Oncol. 1983;1(4):255–62.CrossRefPubMedGoogle Scholar
  7. 7.
    Thumallapally N, et al. Erratum to: Solitary plasmacytoma: population-based analysis of survival trends and effect of various treatment modalities in the USA. BMC Cancer. 2017;17(1):443.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    McLain RF, Weinstein JN. Solitary plasmacytomas of the spine: a review of 84 cases. J Spinal Disord. 1989;2(2):69–74.CrossRefPubMedGoogle Scholar
  9. 9.
    de Waal EG, et al. Progression of a solitary plasmacytoma to multiple myeloma. A population-based registry of the northern Netherlands. Br J Haematol. 2016;175(4):661–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Susnerwala SS, et al. Extramedullary plasmacytoma of the head and neck region: clinicopathological correlation in 25 cases. Br J Cancer. 1997;75(6):921–7.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Remigio PA, Klaum A. Extramedullary plasmacytoma of stomach. Cancer. 1971;27(3):562–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Chim CS, et al. Extramedullary sites of involvement in hematologic malignancies: case 3. Hemorrhagic gastric plasmacytoma as the primary presentation in multiple myeloma. J Clin Oncol. 2002;20(1):344–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Hill QA, et al. Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis. Blood. 2014;124(8):1296–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Paiva B, et al. Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma. Blood. 2014;124(8):1300–3.CrossRefPubMedGoogle Scholar
  15. 15.
    Hill, Q.A., et al., Neoplastic plasma cells are demonstrable at bone marrow sites distant to solitary plasmacytoma of bone and predict for progression to multiple myeloma. ASH Annual Meeting Abstracts, 2006. 108(11): p. 3512-.Google Scholar
  16. 16.
    Hotz MA, et al. Extramedullary solitary plasmacytoma of the head and neck. A clinicopathological study. Ann Otol Rhinol Laryngol. 1999;108(5):495–500.CrossRefPubMedGoogle Scholar
  17. 17.
    Bartl R, et al. Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases. Am J Clin Pathol. 1987;87(3):342–55.CrossRefPubMedGoogle Scholar
  18. 18.
    Caers J, et al. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. J Hematol Oncol. 2018;11(1):10.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Dingli D, et al. Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood. 2006;108(6):1979–83.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Wilder RB, et al. Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. Cancer. 2002;94(5):1532–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Liebross RH, et al. Clinical course of solitary extramedullary plasmacytoma. Radiother Oncol. 1999;52(3):245–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Caers J, et al. The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow-up of multiple myeloma. Haematologica. 2014;99(4):629–37.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Gleeson TG, et al. Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI). Skelet Radiol. 2009;38(3):225–36.CrossRefGoogle Scholar
  24. 24.
    Kropil P, et al. Comparison of whole-body 64-slice multidetector computed tomography and conventional radiography in staging of multiple myeloma. Eur Radiol. 2008;18(1):51–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Liebross RH, et al. Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. Int J Radiat Oncol Biol Phys. 1998;41(5):1063–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Dimopoulos MA, et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol. 2015;33(6):657–64.CrossRefPubMedGoogle Scholar
  27. 27.
    Fouquet G, et al. Impact of initial FDG-PET/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma. Clin Cancer Res. 2014;20(12):3254–60.CrossRefPubMedGoogle Scholar
  28. 28.
    Nanni C, et al. 18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone. In Vivo. 2008;22(4):513–7.PubMedGoogle Scholar
  29. 29.
    Lu YY, et al. FDG PET or PET/CT for detecting intramedullary and extramedullary lesions in multiple Myeloma: a systematic review and meta-analysis. Clin Nucl Med. 2012;37(9):833–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Salaun PY, et al. FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma. Haematologica. 2008;93(8):1269–71.CrossRefPubMedGoogle Scholar
  31. 31.
    Kim PJ, et al. Impact of 18F-fluorodeoxyglucose positron emission tomography before and after definitive radiation therapy in patients with apparently solitary plasmacytoma. Int J Radiat Oncol Biol Phys. 2009;74(3):740–6.CrossRefPubMedGoogle Scholar
  32. 32.
    Zamagni E, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007;92(1):50–5.CrossRefPubMedGoogle Scholar
  33. 33.
    Nanni C, et al. Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging. 2006;33(5):525–31.CrossRefPubMedGoogle Scholar
  34. 34.
    Cavo M, et al. Role of (18)F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18(4):e206–17.CrossRefPubMedGoogle Scholar
  35. 35.
    Warsame R, et al. Trends and outcomes of modern staging of solitary plasmacytoma of bone. Am J Hematol. 2012;87(7):647–51.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Dispenzieri A, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23(2):215–24.CrossRefPubMedGoogle Scholar
  37. 37.
    Caers J, et al. Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physicians. Ann Med. 2013;45(5–6):413–22.CrossRefPubMedGoogle Scholar
  38. 38.
    Katodritou E, et al. Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients. Am J Hematol. 2014;89(8):803–8.CrossRefPubMedGoogle Scholar
  39. 39.
    Holland J, et al. Plasmacytoma. Treatment results and conversion to myeloma. Cancer. 1992;69(6):1513–7.CrossRefPubMedGoogle Scholar
  40. 40.
    Soutar R, et al. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br J Haematol. 2004;124(6):717–26.CrossRefPubMedGoogle Scholar
  41. 41.
    Barosi G, et al. Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). Haematologica. 2004;89(6):717–41.PubMedGoogle Scholar
  42. 42.
    Reed V, et al. Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy. Cancer. 2011;117(19):4468–74.CrossRefPubMedGoogle Scholar
  43. 43.
    Knobel D, et al. Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. BMC Cancer. 2006;6:118.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Frassica DA, et al. Solitary plasmacytoma of bone: Mayo Clinic experience. Int J Radiat Oncol Biol Phys. 1989;16(1):43–8.CrossRefPubMedGoogle Scholar
  45. 45.
    Aviles A, et al. Improved outcome in solitary bone plasmacytomata with combined therapy. Hematol Oncol. 1996;14(3):111–7.CrossRefPubMedGoogle Scholar
  46. 46.
    Bolek TW, Marcus RB, Mendenhall NP. Solitary plasmacytoma of bone and soft tissue. Int J Radiat Oncol Biol Phys. 1996;36(2):329–33.CrossRefPubMedGoogle Scholar
  47. 47.
    Jyothirmayi R, et al. Radiotherapy in the treatment of solitary plasmacytoma. Br J Radiol. 1997;70(833):511–6.CrossRefPubMedGoogle Scholar
  48. 48.
    Tsang RW, et al. Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome. Int J Radiat Oncol Biol Phys. 2001;50(1):113–20.CrossRefPubMedGoogle Scholar
  49. 49.
    Ozsahin M, et al. Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients. Int J Radiat Oncol Biol Phys. 2006;64(1):210–7.CrossRefPubMedGoogle Scholar
  50. 50.
    Weber, D.M., Solitary bone and extramedullary plasmacytoma. Hematology Am Soc Hematol Educ Program, 2005;373–6.Google Scholar
  51. 51.
    Alexander MP, Goodkin DE, Poser CM. Solitary plasmacytoma producing cranial neuropathy. Arch Neurol. 1975;32(11):777–8.CrossRefPubMedGoogle Scholar
  52. 52.
    Alexiou C, et al. Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. Cancer. 1999;85(11):2305–14.CrossRefPubMedGoogle Scholar
  53. 53.
    Burt M, et al. Medical tumors of the chest wall. Solitary plasmacytoma and Ewing’s sarcoma. J Thorac Cardiovasc Surg. 1993;105(1):89–96.PubMedGoogle Scholar
  54. 54.
    Chang MY, et al. Solitary plasmacytoma of bone. J Formos Med Assoc. 1994;93(5):397–402.PubMedGoogle Scholar
  55. 55.
    Galieni P, et al. Solitary plasmacytoma of bone and extramedullary plasmacytoma: two different entities? Ann Oncol. 1995;6(7):687–91.CrossRefPubMedGoogle Scholar
  56. 56.
    Mayr NA, et al. The role of radiation therapy in the treatment of solitary plasmacytomas. Radiother Oncol. 1990;17(4):293–303.CrossRefPubMedGoogle Scholar
  57. 57.
    Kumar S, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–46.CrossRefPubMedGoogle Scholar
  58. 58.
    Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.CrossRefPubMedGoogle Scholar
  59. 59.
    Delauche-Cavallier MC, et al. Solitary plasmacytoma of the spine. Long-term clinical course. Cancer. 1988;61(8):1707–14.CrossRefPubMedGoogle Scholar
  60. 60.
    Dimopoulos MA, et al. Macrofocal multiple myeloma in young patients: a distinct entity with favorable prognosis. Leuk Lymphoma. 2006;47(8):1553–6.CrossRefPubMedGoogle Scholar
  61. 61.
    Harwood AR, Knowling MA, Bergsagel DE. Radiotherapy of extramedullary plasmacytoma of the head and neck. Clin Radiol. 1981;32(1):31–6.CrossRefPubMedGoogle Scholar
  62. 62.
    Pour L, et al. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica. 2014;99(2):360–4.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Short KD, et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia. 2011;25(6):906–8.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Wu P, et al. The impact of extramedullary disease at presentation on the outcome of myeloma. Leuk Lymphoma. 2009;50(2):230–5.CrossRefPubMedGoogle Scholar
  65. 65.
    Blade J, Kyle RA, Greipp PR. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol. 1996;93(2):345–51.CrossRefPubMedGoogle Scholar
  66. 66.
    Blade J, et al. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol. 2011;29(28):3805–12.CrossRefPubMedGoogle Scholar
  67. 67.
    Varga C, et al. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol. 2015;169(6):843–50.CrossRefPubMedGoogle Scholar
  68. 68.
    Papanikolaou X, et al. Incidence, clinical features, laboratory findings and outcome of patients with multiple myeloma presenting with extramedullary relapse. Leuk Lymphoma. 2013;54(7):1459–64.CrossRefPubMedGoogle Scholar
  69. 69.
    Weinstock M, et al. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br J Haematol. 2015;169(6):851–8.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Katodritou E, et al. Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome? Leuk Res. 2009;33(8):1137–40.CrossRefPubMedGoogle Scholar
  71. 71.
    Chang H, et al. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions. Br J Haematol. 2004;127(3):280–4.CrossRefPubMedGoogle Scholar
  72. 72.
    Muchtar E, et al. Myeloma in scar tissue—an underreported phenomenon or an emerging entity in the novel agents’ era? A single center series. Acta Haematol. 2014;132(1):39–44.CrossRefPubMedGoogle Scholar
  73. 73.
    Varettoni M, et al. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010;21(2):325–30.CrossRefPubMedGoogle Scholar
  74. 74.
    Moreau P, et al. Prospective evaluation of magnetic resonance imaging and [(18)F]Fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM Study. J Clin Oncol. 2017;35(25):2911–8.CrossRefPubMedGoogle Scholar
  75. 75.
    Usmani SZ, et al. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood. 2013;121(10):1819–23.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Zamagni E, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118(23):5989–95.CrossRefPubMedGoogle Scholar
  77. 77.
    Jurczyszyn A, et al. Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. Leuk Lymphoma. 2016;57(9):2071–6.CrossRefPubMedGoogle Scholar
  78. 78.
    Gozzetti A, et al. Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients. Cancer. 2012;118(6):1574–84.CrossRefPubMedGoogle Scholar
  79. 79.
    Fassas AB, et al. Myeloma of the central nervous system: strong association with unfavorable chromosomal abnormalities and other high-risk disease features. Leuk Lymphoma. 2004;45(2):291–300.CrossRefPubMedGoogle Scholar
  80. 80.
    Paludo J, et al. Myelomatous Involvement of the Central Nervous System. Clin Lymphoma Myeloma Leuk. 2016;16(11):644–54.CrossRefPubMedGoogle Scholar
  81. 81.
    Paubelle E, et al. Complete remission with bortezomib on plasmocytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including hematopoietic stem cell transplantation: possible enhancement of graft-vs-tumor effect. Leukemia. 2005;19(9):1702–4.CrossRefPubMedGoogle Scholar
  82. 82.
    Patriarca F, et al. Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation. Haematologica. 2005;90(2):278–9.PubMedGoogle Scholar
  83. 83.
    Anagnostopoulos A, et al. Treatment of relapsed/refractory multiple myeloma with thalidomide-based regimens: identification of prognostic factors. Leuk Lymphoma. 2004;45(11):2275–9.CrossRefPubMedGoogle Scholar
  84. 84.
    Avigdor A, et al. Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma. Leuk Lymphoma. 2001;42(4):683–7.CrossRefPubMedGoogle Scholar
  85. 85.
    Rosinol L, et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica. 2004;89(7):832–6.PubMedGoogle Scholar
  86. 86.
    Sonneveld P, et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol. 2013;31(26):3279–87.CrossRefPubMedGoogle Scholar
  87. 87.
    Mateos MV, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 2010;28(13):2259–66.CrossRefPubMedGoogle Scholar
  88. 88.
    Durie BG, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomized, open-label, phase 3 trial. Lancet. 2017;389(10068):519–27.CrossRefPubMedGoogle Scholar
  89. 89.
    San Miguel JF, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906–17.CrossRefPubMedGoogle Scholar
  90. 90.
    Barlogie B, et al. The Arkansas approach to therapy of patients with multiple myeloma. Best Pract Res Clin Haematol. 2007;20(4):761–81.CrossRefPubMedPubMedCentralGoogle Scholar
  91. 91.
    Rosinol L, et al. Allogeneic hematopoietic SCT in multiple myeloma: long-term results from a single institution. Bone Marrow Transplant. 2015;50(5):658–62.CrossRefPubMedGoogle Scholar
  92. 92.
    Laura R, et al. Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur J Haematol. 2006;76(5):405–8.CrossRefPubMedGoogle Scholar
  93. 93.
    Durie BG, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467–73.CrossRefPubMedGoogle Scholar
  94. 94.
    Mateos MV, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013;369(5):438–47.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Despina Fotiou
    • 1
  • Meletios A. Dimopoulos
    • 1
  • Efstathios Kastritis
    • 1
  1. 1.Department of Clinical Therapeutics, School of MedicineNational and Kapodistrian University of AthensAthensGreece

Personalised recommendations